newsfilter
← Latest News
PR Newswire·

Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2022 Financial Results

THE-630 Phase 1/2 clinical trial actively enrolling patients with advanced gastrointestinal stromal tumors (GIST); initial data expected in 1H 2023 On track to nominate development candidate for fourth-generation epidermal growth factor receptor (EGFR)